APAC Bladder Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Industry Research Report

APAC Bladder Cancer Therapeutics & Diagnostics Market Size

View Global Report

Study Period	2019 - 2029
Base Year For Estimation	2023
Forecast Data Period	2024 - 2029
Historical Data Period	2019 - 2022
CAGR	5.00 %
Major Players *Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

APAC Bladder Cancer Therapeutics & Diagnostics Market Analysis

Asia-Pacific Bladder Cancer Therapeutics and Diagnostics market is expected to register a CAGR of 5% during the forecast period, owing to increasing burden of bladder cancer and new diagnosis & treatments coming up in the market. According to Globocan, 2018, around 37,293 new cases of bladder cancer were registered in Japan and around 9,943 deaths occurred due to it. This calls for the need of early treatment and diagnosis. Furthermore, new drugs are being developed for the treatment of bladder cancer. In 2020, BeiGene Ltd., recieved an approval from China National Medical Products Administration (NMPA) for anti-PD-1 antibody tislelizumab in the treatment of locally advanced or metastatic urothelial carcinoma (UC). Hence, these factors are expected to drive the growth of the market.

APAC Bladder Cancer Therapeutics & Diagnostics Market Trends

This section covers the major market trends shaping the APAC Bladder Cancer Therapeutics & Diagnostics Market according to our research experts:

Bladder Ultrasound is Expected to Show a Steady Growth During the Forecast Period

Bladder Ultrasound is one of the type of diagnostic device which uses sound waves to detect and analyze the cancer present in the bladder. The growing incidence of bladder cancer and new devices are being developed for the diagnosis of cancer are expected to stimulate the growth in this segment. According to the Globocan, 2018, almost 4,249 incidences of bladder cancer were observed in the Korea Republic of with around 1,712 deaths. Ultrasound is the most common method used in diagnosing the early stages of cancer due to its specificity. Hence, it is expected to boost the demand for ultrasound devices in the market during the forecast period.

Understand The Key Trends Shaping This Market

Download PDF

APAC Bladder Cancer Therapeutics & Diagnostics Industry Overview

Some of the key players in the market are AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Novartis, Pfizer, Sanofi, Endo Pharmaceuticals Inc. and Johnson & Johnson. Companies are constantly indulged in developing the products related to diagnosis and treatment of the bladder cancer to grow their presence in the market. In 2018, Merck recieved an approval from Japanese Ministry of Health, Labor and Welfare (MHLW) for it's product Keytruda (MSD) which is used for the treatment of urothelial cancer patients.

APAC Bladder Cancer Therapeutics & Diagnostics Market Leaders

F. Hoffmann-La Roche Ltd
Johnson & Johnson
Endo Pharmaceutical Inc.
AstraZeneca Plc
Bristol-Myers Squibb Company

*Disclaimer: Major Players sorted in no particular order

Need More Details on Market Players and Competitors?

Download PDF

APAC Bladder Cancer Therapeutics & Diagnostics Market Report - Table of Contents

1. INTRODUCTION
1. 1.1 Study Assumptions
2. 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. 4.1 Market Overview
2. 4.2 Market Drivers
  1. 4.2.1 Increasing Burden of Bladder Cancer
  2. 4.2.2 Innovation in Drug Development
3. 4.3 Market Restraints
  1. 4.3.1 Increased Used of Generic Drugs
4. 4.4 Porter's Five Force Analysis
  1. 4.4.1 Threat of New Entrants
  2. 4.4.2 Bargaining Power of Buyers/Consumers
  3. 4.4.3 Bargaining Power of Suppliers
  4. 4.4.4 Threat of Substitute Products
  5. 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. 5.1 By Product
  1. 5.1.1 By Therapeutics
    1. 5.1.1.1 Chemotherapy
    2. 5.1.1.2 Immunotherapy
    3. 5.1.1.3 Others
  2. 5.1.2 By Diagnostics
    1. 5.1.2.1 Cystoscopy
    2. 5.1.2.2 Bladder Ultrasound
    3. 5.1.2.3 Urinalysis
    4. 5.1.2.4 Others
2. 5.2 By Cancer Type
  1. 5.2.1 Transitional Cell Bladder Cancer
  2. 5.2.2 Squamous Cell Bladder Cancer
  3. 5.2.3 Others
3. 5.3 Geography
  1. 5.3.1 Asia-Pacific
    1. 5.3.1.1 China
    2. 5.3.1.2 Japan
    3. 5.3.1.3 India
    4. 5.3.1.4 Australia
    5. 5.3.1.5 South Korea
    6. 5.3.1.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
1. 6.1 Company Profiles
  1. 6.1.1 AstraZeneca Plc
  2. 6.1.2 Bristol-Myers Squibb Company
  3. 6.1.3 Eli Lilly & Company
  4. 6.1.4 Endo Pharmaceuticals Inc.
  5. 6.1.5 F. Hoffmann-La Roche Ltd
  6. 6.1.6 GlaxoSmithKline
  7. 6.1.7 Novartis
  8. 6.1.8 Pfizer
  9. 6.1.9 Sanofi
  10. 6.1.10 Johnson & Johnson
2. *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections

Get Price Break-up Now

APAC Bladder Cancer Therapeutics & Diagnostics Industry Segmentation

Bladder cancer is a type of tumor that occurs in the cells of the bladder. It grows rapidly and shows uncontrolled growth in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. The Asia-Pacific Bladder Cancer Therapeutics and Diagnostics market is segmented by Product, by Cancer Type, and Geography.

By Product

By Therapeutics
	Chemotherapy
	Immunotherapy
	Others

By Diagnostics
	Cystoscopy
	Bladder Ultrasound
	Urinalysis
	Others

By Cancer Type
		Transitional Cell Bladder Cancer
		Squamous Cell Bladder Cancer
		Others

Geography

Asia-Pacific
	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific

Need A Different Region Or Segment?

Customize Now

APAC Bladder Cancer Therapeutics & Diagnostics Market Research FAQs

What is the current Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market size?

The Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market is projected to register a CAGR of 5% during the forecast period (2024-2029)

Who are the key players in Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market?

F. Hoffmann-La Roche Ltd, Johnson & Johnson, Endo Pharmaceutical Inc., AstraZeneca Plc and Bristol-Myers Squibb Company are the major companies operating in the Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market.

What years does this Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market cover?

The report covers the Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Industry Report

Statistics for the 2024 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Study Period:
CAGR:
Countries/ Region Covered:
Major Players:

Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)